Global Antibiotic R&D Partnership (GARDP)

GARDP backs Debiopharm’s Swiss-developed compound to treat drug-resistant gonorrhoea infections. We are thrilled to announce that GARDP will support Debiopharm to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae. The compound’s preclinical development has been completed with ongoing support from CARB-X. GARDP and Debiopharm are now planning to develop the compound for regulatory approval and help make the final product available and affordable to treat patients worldwide.  Learn more: https://lnkd.in/dW4GdEat #AMR #AntibioticDevelopment #GlobalHealth #DrugResistance #HealthInnovation

On 14 January, Debiopharm and GARDP announced a new partnership to support the development of Debio 1453, a compound targeting drug-resistant gonorrhoea. Why This Matters: 🦠 Gonorrhoea is becoming harder to treat: Multidrug-resistant N. gonorrhoeae strains are spreading globally, reducing treatment options and placing it on World Health Organization’s high-priority pathogen list. New treatments are urgently needed. 💊 The need for innovation: Gonorrhoea has developed resistance to nearly all antibiotics, leaving ceftriaxone as the last globally recommended treatment. Reports of ceftriaxone-resistant outbreaks highlight the urgent need for new antibiotics. 🔗 Read more: https://lnkd.in/d-uAkb3F #AMR #Antibiotics #Innovation #Partnerships #DrugDevelopment

🇮🇳 India takes on superbugs with innovation Pharmaceutical companies in India are shifting their focus from producing generics to developing innovative antibiotics, addressing the growing crisis of drug-resistant infections. Why this matters: 🦠 India is at the epicentre: Home to some of the most resistant bacteria, India’s population faces a high burden of drug-resistant infections. 💊 From generics to innovation: With a robust pharmaceutical infrastructure, India is uniquely positioned to lead antibiotic development and ensure access worldwide. 👉 Read more in @NikkeiAsia: https://lnkd.in/dBhheZJj #AMR #GlobalHealth #Innovation #Antibiotics #India

💡 Novel antibiotics: Regional research is (half) the solution Antibiotic resistance is rising globally, with middle- and lower-income countries facing the greatest threat from some of the most resistant bacteria. "We should try to make sure we prioritise those antibiotics which we really know are going to address the priority pathogens and where we're seeing the greatest burden of the disease, in terms of infections." Dr Seamus O'Brien, R&D Director at GARDP. While each region faces unique challenges, regional research efforts not only address local needs but can also deliver significant global health benefits by ensuring effective and accessible treatments for everyone. Read more in DW: https://lnkd.in/dZ9UMWfM

Join us in February 2025 for the next Antimicrobial Chemotherapy Conference. Take a deep dive into antimicrobial R&D with sessions on drug discovery, pre and clinical antimicrobial development, and antifungal development pipeline. This free online conference is organised by GARDP and the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with Cepid Aries and Fiocruz. 📆4 & 5 February 2025 Register now for free: https://lnkd.in/dRQqHJwJ

🌍 GARDP: Closing critical gaps in antibiotic access Access to effective antibiotics remains a major global challenge, especially in developing regions. Barriers to discovering and delivering antibiotics for multidrug-resistant infections highlight the urgent need for action. In this Antimicrobial Agents and Chemotherapy Journal episode, learn more about : 🌟 GARDP’s pivotal role in addressing antimicrobial resistance (AMR) 💊 Strategies to improve access to life-saving antibiotics 🔬 The future of antimicrobial research and development Featuring: • Dr Jennifer Cohn, Director, Global Access • Susana Ribeiro, Regional Head, Latin America 👉 Listen here: https://lnkd.in/dDsCXyzg #AMR #PowerOfAntibiotics #GARDP #Podcast

📢 Attention antimicrobial researchers! Your insights matter. The 9th AMR Conference will host a high-level panel on “Making the Most of External Expertise.” This is your opportunity to shape the conversation. How you can help: The BEAM Alliance and GARDP are running a survey to understand: • How researchers access knowledge and training. • Whether expert advice is sufficiently available. • Gaps faced by those seeking guidance. Your input will guide discussions during the session and help tackle key challenges in antimicrobial research. 🔗 Complete the survey here: https://lnkd.in/eheEQ_Nq 📍 AMR Conference | 25–26 February | Basel, Switzerland #AMR #AntibioticResearch #GlobalHealth #Collaboration

We must ensure that antimicrobial resistance (AMR) remains a global priority. As we reflect on 2024, there has been a pivotal shift: ensuring sustainable access to effective antibiotics is critical in the fight against AMR. However, as Rohit Malpani, Advisor at GARDP, puts it: "Sustaining attention on AMR is one of the key challenges for 2025." Missed the UN Foundation 2024 in Review: AMR Community Stock-Take? No worries—the webinar recording is now available. Dive into key insights from an impactful year, including milestones, challenges, and actionable steps to keep AMR high on the global agenda in 2025. 👉 Watch the webinar here: https://lnkd.in/g5NPCDpA

Think your body becomes resistant to antibiotics? Here’s why you’re wrong. In an insightful interview with First Check, Dr Manica Balasegaram, GARDP’s Executive Director, addresses a widespread myth about antimicrobial resistance (AMR). "It’s not the body, but bacteria, that evolve to resist antibiotics," he said, emphasizing the urgent need for better education and awareness. Dr Balasegaram highlights key points: 💊 Antibiotics target bacterial infections—not viruses or other illnesses. 🚫 Misuse of antibiotics accelerates resistance. 📚 We must rethink how health and biology are taught to improve understanding and action against AMR. Read the interview here: https://lnkd.in/g_DijQ3f #AMR #AntibioticAwareness #PowerOfAntibiotics #GlobalHealth

Join us in February 2025 for the next Antimicrobial Chemotherapy Conference. Take a deep dive into antimicrobial R&D with sessions on drug discovery, preclinical antimicrobial development, and antifungal development pipeline. This free, online conference is organized by GARDP and the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with Cepid Aries and Fiocruz. 📆4 & 5 February 2025 Register now for free: https://lnkd.in/dRQqHJwJ